Persistent Low‐Output Neonatal Chylothorax: How Long Are We Justified to Wait for Pleurodesis in Partial Responders?
Pediatric Pulmonology · 2025
DOI: 10.1002/ppul.71311 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von G Rollo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neonatal and Pediatric Surgery, Bambino Gesù Children's Hospital IRCCS, Roma, Italy. Hauptthemen laut MEDLINE: Pleurodesis, Chylothorax. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This study was supported by the Italian Ministry of Health with "Current Research funds". This study did not receive other types of grants from funding agencie….
Abstract (Originalsprache)
Aims
The aim of our study was to review our experience regarding the management of neonatal chylothorax, with particular focus on outcomes of partial responders.
Methods
We conducted a retrospective analysis of neonatal chylothorax cases between January 2015 and December 2023. First‐line management included drainage, fasting, parenteral nutrition, and octreotide. Good responders had a drainage output of 10 ml/kg/day or >100 ml/day for 5 days with complications. Partial responders continued conservative management, while non‐responders received second‐line treatment with bedside iodopovidone chemical pleurodesis.
Results
Thirty‐five newborns (15 females, 20 males) were diagnosed with chylothorax, 11 congenital and 24 acquired (18 CDH, 5 esophageal atresia, 1 caval thrombosis). After first‐line treatment, 7 (20%) were good responders, 19 (54%) were partial responders, and 9 (26%) were non‐responders. Non‐responders received iodopovidone pleurodesis, which resolved the condition in all cases (median time to resolution was 4 days). Complications during hospitalization included 8 cases of sepsis (1 fatal), 5 of atelectasis (4 related to pleurodesis), and 4 venous thromboses. Partial responders had significantly more sepsis ( p = 0.029) but less atelectasis ( p = 0.025) compared to non‐responders, with similar resolution times and hospital stays. After a median follow‐up of 3 years, there were no recurrences or thyroid dysfunction in the iodopovidone group.
Conclusions
First‐line conservative management, although initially appropriate, can lead to serious morbidity if prolonged. Timely second‐line treatment for partial responders with low‐output chylothorax can minimize morbidity and mortality. Bedside chemical pleurodesis with iodopovidone is a safe and effective second‐line treatment for refractory neonatal chylothorax.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neonatal and Pediatric Surgery, Bambino Gesù Children's Hospital IRCCS, Roma, Italy.
- University of "Tor Vergata", Rome, Italy.
- Neonatal Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.
ORCID-Profile: G Rollo
Förderung
- This study was supported by the Italian Ministry of Health with "Current Research funds". This study did not receive other types of grants from funding agencie…
Zitieren
APA
Rollo, G., Zarfati, A., Burini, G., Valfre, L., Iacusso, C., Capolupo, I., Iacobelli, B. D., Bagolan, P., Conforti, A., & Fusaro, F. (2025). Persistent Low‐Output Neonatal Chylothorax: How Long Are We Justified to Wait for Pleurodesis in Partial Responders?. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71311
Vancouver
Rollo G, Zarfati A, Burini G, Valfre L, Iacusso C, Capolupo I, et al. Persistent Low‐Output Neonatal Chylothorax: How Long Are We Justified to Wait for Pleurodesis in Partial Responders?. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71311
BibTeX
@article{Rollo2025,
author = {Rollo, G and Zarfati, A and Burini, G and Valfre, L and Iacusso, C and Capolupo, I and Iacobelli, B D and Bagolan, P and Conforti, A and Fusaro, F},
title = {Persistent Low‐Output Neonatal Chylothorax: How Long Are We Justified to Wait for Pleurodesis in Partial Responders?},
journal = {Pediatric Pulmonology},
year = {2025},
doi = {10.1002/ppul.71311}
}
EUVIMED